MiniMed Raises 2027 Guidance Following 17% Revenue Surge in Q1

Key Facts

1MiniMed reported net sales of $843 million, a 17% increase, for the first quarter of fiscal year 2027.

2The company raised its full-year fiscal 2027 organic revenue growth guidance.

3U.S. net sales growth accelerated to 13% alongside progress in FDA submissions for new products.

Reflecting the growing strength of the medical technology sector, MiniMed announced robust financial results for the first quarter of fiscal year 2027. The company reported net sales of $843 million, representing a 17% increase compared to the prior year. This strong performance led management to raise its full-year organic revenue growth guidance, fueled by high demand for diabetes technology across both domestic and international markets.

According to reports, U.S. net sales growth accelerated to 13%, coinciding with the company's progress in FDA submissions for its new product pipeline. This growth occurred alongside operational advancements for the MiniMed Fit and Flex systems. Based on these facts, the company updated its fiscal 2027 outlook, signaling management's confidence in sustaining current momentum within the diabetes care industry.

Per market data, specific price levels for MMED were unavailable at close September 1, 2026, leaving qualitative sentiment as the primary driver for now. Traders should watch for upcoming regulatory updates from the FDA as potential catalysts. Additionally, recent economic data showing changes in U.S. Personal Income and Spending may impact consumer health expenditures, providing broader context for the medical device market.